ISM9182A
/ Insilico Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
ISM9182A, a novel HPK1 inhibitor, exhibits immune modulatory activity and robust monotherapy anti-tumor effects in preclinical studies
(AACR 2024)
- "In a CT-26 murine syngeneic mouse model, oral administration of ISM9182A exhibited potent antitumor effects with p-SLP76 inhibition in both murine spleen and tumor, without body weight loss. In summary, ISM9182A is a potent and selective HPK1 inhibitor and a promising immuno-oncology agent."
IO biomarker • Monotherapy • Preclinical • Oncology • CD80 • CD83 • CD86 • IFNG • IL1B • IL2 • LCP2 • TNFA
1 to 1
Of
1
Go to page
1